New Research Questions the Safety of CBN as a Popular Natural Sleep Aid

Cannabinol (CBN) has rapidly ascended the ranks of the modern wellness industry, finding its way into a vast array of gummies, tinctures, and sleep capsules marketed as a natural, gentle, and non-habit-forming solution for those struggling with insomnia. Promoted as the "sleepy" cousin to the more famous cannabinoids, CBN is frequently touted as a mild, plant-based way to wind down. However, emerging research from the University of Connecticut is casting a long shadow over these claims, suggesting that the compound may carry significant risks that have been largely overlooked by both the market and the public.

The findings, published in the November issue of the academic journal Drug and Alcohol Dependence, suggest that repeated exposure to CBN may trigger physical dependence in biological models. This revelation challenges the prevailing narrative that CBN is a benign, herbal sleep supplement and raises urgent questions regarding the long-term safety of its widespread consumption. As the supplement market continues to expand with minimal regulatory oversight, researchers are sounding a note of caution for the millions of consumers who rely on these products nightly.

“CBN is everywhere right now. Gummies, tinctures, capsules, and it’s marketed as a safe, herbal sleep supplement,” explains Steven Kinsey, a professor in UConn’s Elisabeth DeLuca School of Nursing. “Our findings suggest consumers should be aware that repeated use may carry risks that we are only just beginning to understand.”

Popular Sleep Aid Shows Effects Similar to THC

To understand the potential impact of CBN, it is necessary to contextualize it within the broader landscape of the cannabis plant. While most consumers are familiar with the psychoactive effects of tetrahydrocannabinol (THC) and the anti-inflammatory, non-intoxicating profile of cannabidiol (CBD), CBN occupies a more ambiguous middle ground. It is a naturally occurring compound, but it is often formed as cannabis ages and the THC degrades. Because it is generally considered less potent or psychoactive than THC, it has been embraced by the wellness industry as a safer alternative for evening use.

However, the team at the University of Connecticut discovered that this perception of mildness may be misleading. In their experiments, researchers observed that CBN interacts with the same biological systems as its more notorious counterparts, leading to distinct physiological responses indicative of drug dependence.

In a series of controlled experiments, researchers administered CBN to mice twice daily over a period of three consecutive days. The results were telling: as the treatment progressed, the mice exhibited a diminished response to the compound, a clear indicator that they had developed a tolerance to it. More concerning was the behavior observed when the compound was withdrawn. The mice displayed physical symptoms of withdrawal—specifically head twitching and paw fluttering—which are recognized by scientists as being comparable to the physical tremors often seen in human drug withdrawal.

Perhaps most surprising was a secondary experiment that tested the similarity between CBN and THC. The researchers trained mice to recognize and react to the psychoactive effects of THC. When these same mice were subsequently administered CBN, they responded in a nearly identical fashion. This strongly suggests that, at least within the biological pathways of the mice, the subjective experience of the two compounds overlaps significantly. These results provide compelling evidence that CBN, despite its reputation as a "minor" and gentle cannabinoid, engages with the same receptor systems that facilitate dependence on THC.

Scientists Raise Concerns About CBN Sleep Supplements

The timing of this research is critical. The market for minor cannabinoids has exploded in recent years, often outpacing the scientific community’s ability to conduct rigorous, long-term safety studies. Because these products are frequently sold as dietary supplements rather than pharmaceuticals, they occupy a regulatory gray area where efficacy and safety claims are often made without the level of scrutiny required for traditional medications.

Lead author of the study, Olivia Vanegas, a Ph.D. candidate, notes that the current landscape is increasingly volatile. “The marketing of minor cannabinoids is pretty wild right now,” Vanegas observes. “There are so many therapeutic claims about these drugs, but we really don’t know much about their potential risks, especially with repeated use.”

The reliance on these supplements for sleep quality is particularly concerning given the historical precedent for sleep aids. Over the last century, medical history has been punctuated by instances where substances initially introduced as helpful, mild, and "natural" treatments for sleep or anxiety were later found to carry profound risks of addiction and habit formation once their long-term effects were fully documented. By the time the risks of dependence were understood, millions of people had already integrated these substances into their nightly routines. Researchers worry that CBN may be following a similar trajectory, being marketed as a panacea for sleeplessness before the scientific community has established a baseline for safe, chronic usage.

Furthermore, there is a distinct lack of data regarding how CBN impacts human sleep architecture. While users frequently report feeling "relaxed" or "drowsy," it remains unclear whether the compound actually improves the quality of restorative sleep or merely induces a state of sedation that could eventually mask underlying sleep disorders. Without comprehensive human clinical trials, the transition from animal models to real-world consumer use is a leap that scientists are currently unwilling to endorse.

Potential Benefits Come With Unanswered Safety Questions

The researchers at UConn were careful to note that their work was not intended to demonize the compound entirely. In fact, their investigation identified several potentially beneficial properties of CBN, particularly its anti-inflammatory capabilities. Even at lower doses that did not trigger psychoactive effects or the markers of dependence seen in the higher-dose trials, the compound demonstrated an ability to mitigate inflammation.

However, these potential therapeutic benefits were tempered by another significant finding regarding immune system health. During the study, researchers simulated a bacterial challenge to observe how the body’s immune system would respond in the presence of CBN. They found that the compound appeared to dampen the body’s ability to defend itself against the simulated threat. In a real-world scenario, this could imply that frequent users might be more susceptible to infections, as their immune response could be compromised by the presence of the cannabinoid. This is particularly relevant for the elderly or those with existing health conditions, who are often the target demographic for sleep-aid marketing.

While the data from the study is robust, the researchers emphasize the limitations inherent in animal testing. Because these experiments were conducted on mice, they do not provide an automatic, one-to-one confirmation that CBN will cause physical dependence or immune suppression in humans. Human physiology is far more complex, and factors such as dosage, frequency, and individual metabolic differences mean that additional, human-centric studies are essential before any definitive conclusions can be drawn about the long-term safety of the compound.

The study serves as a necessary wake-up call for an industry that has prioritized rapid growth over clinical validation. As consumers continue to reach for these products to solve their sleep issues, the medical community is urging a more cautious approach. The allure of a "natural" fix is strong, but the scientific reality appears to be far more nuanced.

“CBN may still have therapeutic value,” Kinsey concludes. “But until we know more about dosing and long-term effects, the message for consumers is simple: buyer beware.” Until further, large-scale clinical trials can clarify how this cannabinoid interacts with the human body over weeks and months of use, the status of CBN as a safe, nightly sleep aid remains, at best, unproven, and at worst, a potential risk to public health.

Share:

rifanmuazin writes for Stepping Stones Center.